News
Gilead’s COVID-19 drug remdesivir bags US approval
Gilead’s antiviral treatment remdesivir has been approved by the US Food and Drug Administration (FDA) for the treatment of COVID-19 patients requiring hospitalisation.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Gilead’s antiviral treatment remdesivir has been approved by the US Food and Drug Administration (FDA) for the treatment of COVID-19 patients requiring hospitalisation.